Patient release after Lu-177 DOTATATE and Lu-177 PSMA 617 therapies

被引：0
|
作者：
Mair, C. [1 ]
Warwitz, B. [1 ]
Buxbaum, S. [1 ]
Virgolini, I. J. [1 ]
机构：
[1] LKH Univ Kliniken Innsbruck, Univ Klin Nukl Med, Innsbruck, Austria
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2017年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0057
引用
收藏
页码：S454 / S454
页数：1
相关论文
共 50 条
  • [1] Serial Dosimetry in Peptide Receptor Radionuclide Therapy using Lu-177 DOTATATE or Lu-177 DOTATOC in the same Patient
    Schuchardt, C.
    Kulkarni, H.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S139 - S139
  • [2] Dosimetry using Lu-177 DOTATATE, Lu-177 HA-DOTATATE and Lu-177 DOTATOC: Comparative Results in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT)
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Shahinfar, M.
    Shafaei, S.
    Kropf, S.
    Wester, H. J.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S224 - S225
  • [3] Establishing a Lu-177 Dotatate Therapy Program
    Snyder, W.
    Harpool, K.
    Swanson, J. W.
    Schantz, P.
    Phan, A.
    Dick, J. S.
    Cavanaugh, S. X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E499 - E500
  • [4] Lu-177 DOTATATE Retreatment: Efficacy and Toxicity
    Santillan, N.
    Ferreira, B.
    Gnanasegaran, G.
    Navalkisoor, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S757 - S757
  • [5] Lutetium Lu-177 Dotatate Flare Reaction
    Salner, Andrew L.
    Blankenship, Bette
    Dunnack, Hayley
    Niemann, Christopher
    Bertsch, Helaine
    ADVANCES IN RADIATION ONCOLOGY, 2021, 6 (01)
  • [6] LU-177 DOTATATE THERAPY IN PATIENTS WITH NETS
    Hosking, E.
    McKay, E.
    Browne, E.
    Thomas, D.
    Liauw, W.
    Morris, D.
    Chu, F.
    Hayes, A.
    Butler, P.
    INTERNAL MEDICINE JOURNAL, 2015, 45 : 18 - 18
  • [7] Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE
    Josephine Graf
    Ulrich-Frank Pape
    Henning Jann
    Timm Denecke
    Ruza Arsenic
    Winfried Brenner
    Marianne Pavel
    Vikas Prasad
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 881 - 894
  • [8] PSMA Radioligand Therapy of Metastasized Prostate Cancer Using Lu-177 PSMA I&T and Lu-177 PSMA-617: First comparative Dosimetric Results
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Shahinfar, M.
    Singh, A.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S36 - S37
  • [9] PSMA Radioligand Therapy (PRLT) using Lu-177 PSMA I&T and Lu-177 PSMA-617: Intra-individual comparison of kinetics and dosimetry
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Shahinfar, M.
    Singh, A.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S214 - S214
  • [10] Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE
    Graf, Josephine
    Pape, Ulrich-Frank
    Jann, Henning
    Denecke, Timm
    Arsenic, Ruza
    Brenner, Winfried
    Pavel, Marianne
    Prasad, Vikas
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (04) : 881 - 894
12345